Clinical Trials Browser

Phase 1/2 × Pemetrexed × 30 days × Clear all

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02535312 2026-03-18

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05098132 2026-03-18

SYNERGY-101

Phase 1/2 Recruiting

364 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

60 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

450 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

596 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06173505 2026-03-13

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Phase 1/2 Terminated

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05410145 2026-03-12

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Phase 1/2 Recruiting

442 enrolled

KRAS P.G12C

NCT05636267 2026-03-09

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase 1/2 Terminated

59 enrolled

Thoracic

NSCLC

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2 Recruiting

616 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07020221 2026-03-09

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Recruiting

366 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06772623 2026-02-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

252 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06996782 2026-02-24

ALTAIR

Phase 1/2 Recruiting

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05789082 2026-02-20

KRAScendo 170

Phase 1/2 Recruiting

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung